ctDNA: Advancing Precision Cancer Management
*Corresponding Author: Andrew K. Brooks, Harbor Cancer Institute, USA, Email: abrooks@harborcancerinstitute.orgReceived Date: Nov 01, 2025 / Accepted Date: Dec 01, 2025 / Published Date: Dec 01, 2025
Citation: Brooks AK (2025) ctDNA: Advancing Precision Cancer Management. jcd 09: 327.DOI: 10.4172/2476-2253.1000327
Copyright: © 2025 Andrew K. Brooks This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permitsunrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
Abstract
Circulating tumor \textit{DNA} (ctDNA) analysis in liquid biopsies is revolutionizing cancer management. This non-invasive
approach offers dynamic insights into tumor biology, enabling early detection, precise treatment monitoring, and identification of
minimal residual disease. Across various cancer types, ctDNA guides therapeutic decisions, predicts immunotherapy responses, and
reveals resistance mechanisms. Advances in technology, including epigenetic marker analysis, continue to enhance its sensitivity
and specificity. While challenges remain in standardization and early-stage detection, ctDNA holds immense potential to personalize
oncology and improve patient outcomes.
